Biosimilar Bridging Study Waivers: Public Health Prerogative Or Trade Secret ‘Taking’?

 
• By Sue Sutter
  
Chess Kings facing each other as a business concept - merger & partnership, or showdown, corporate takeover, strategy, competition, opposition, confrontation, politics, leadership, challenge, survival
Who will control the board – public health or proprietary information arguments?
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics